Encouraging early results with GS-9973 for CLL and NHL
Encouraging early results with GS-9973 for CLL and NHL
Benefit of lenalidomide and low-dose dexamethasone over standard therapy for multiple myeloma
Gemtuzumab improves event free survival for paediatric acute myeloid leukaemia (AML)
PIK3CA gene mutations make HER2- and hormone receptor-positive breast cancers treatment-resistant
Avoiding radiotherapy is an option for some older patients with breast cancer
New agents in CLL
Chronic lymphocytic leukaemia: A new treatment era is born
2013 ecancer highlights
Patient information needs in biomarkers and biobanking
Cancer cells and the immune system: a natural story?
Immuno-Oncology: the next new paradigm in cancer treatment? Chairman's welcome and introduction
Why are Immuno-Oncology compounds different?